Möchten Sie immer auf dem neuesten Stand bleiben?

Pharming today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS) in New Orleans, LA.

Pharming Group reports first quarter 2026 financial results; on track for Joenja® U.S. pediatric label expansion and launches in Japan and Europe in 2026.

Pharming to report first quarter 2026 financial results & provide a business update on May 7, 2026 & host conference call 13:30 CEST/07:30 EDT.

Pharming Group N.V. 2026 Annual General Meeting to be be held on Thursday May 28, 2026, at 14:00 CET. Meeting documents available on website Pharming.com.

Pharming announced that management will participate in investor conferences Needham Virtual Healthcare and Kempen Life Sciences Conferences in April 2026.

Pharming Group today announced filing of its 2025 Annual Report and Annual Report on Form 20-F, available at annualreport.pharming.com.

Pharming announces positive CHMP opinion for Joenja® (leniolisib) for the treatment of APDS in adult and pediatric patients 12 years and older

First approved treatment in Japan for activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS)Approval is based on positive Phase III data from multinational and Japanese studies in patients...

Pharming Group reports fourth quarter and full year 2025 financial results, delivering strong revenue growth and profitability with positive cash flow

Pharming to report 4th quarter full year 2025 financial results & provide a business update on March 12, 2026 & host conference call 13:30 CET/08:30 EDT.